Download Library

Download Library

Document Type
Jefferies London Healthcare Conference, London, UK
Jefferies London Healthcare Conference, London, UK
Interim Report for the First Nine Months of 2017
Interim Report for the First Nine Months of 2017
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax®-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy – ESGO E-poster – November 2017 (Concin)
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Mo
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Mo
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone vs Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant (ALCYONE) - ASH abstract - November 2017 (Mateos)
Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone vs Bortezomib, Melphalan, and Prednisone in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant (ALCYONE) - ASH abstract - November 2017 (Mateos)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - Novembe
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - Novembe
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - Novemb
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - Novemb
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
Genmab First Nine Months of 2017 Results Presentation
Genmab First Nine Months of 2017 Results Presentation
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A phase I/II safety study of tisotumab vedotin (HuMax-TF-ADC) in patients with solid tumors
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
A phase IIa study of tisotumab vedotin (HuMax-TF-ADC) in patients with relapsed, recurrent and/or metastatic cervical cancer
Investor Presentation, September 2017
Investor Presentation, September 2017
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)